Immuneering Corporation - Class A Common Stock Share · US45254E1073 · IMRX (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Immuneering Corporation - Class A Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

01.05.2026 21:09

Current Prices from Immuneering Corporation - Class A Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	IMRX	USD	01.05.2026 21:09	5,41 USD	0,17 USD +3,24 %
IEX	IMRX	USD	01.05.2026 19:59	5,38 USD	0,14 USD +2,67 %

Share Float & Liquidity

Free Float 69,50 %

Shares Float 25,23 M

Shares Outstanding 36,3 M

Company Profile for Immuneering Corporation - Class A Common Stock Share

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.